Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting
Data highlights the Company’s commitment to advancing TMS and improving patient outcomesMALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Neuronetics,...
Neuroscience
Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference
PALO ALTO, Calif. and MIAMI, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the...
NeuroStar® Expands “Tap Into Possibility” Campaign in Honor of Mental Health Awareness Month
Campaign features patients’ experiences to support others with depression A Media Snippet accompanying this announcement is available by clicking on the...
Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer
Strategic role strengthens NeuroStar® Advanced Therapy commercialization teamMALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a...
Neuronetics Announces Expanded TMS Access through United HealthCare
UHC Medicare Advantage plans in NGS states expand access via NPPsMALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc....
Psychedelic Science Announces Sessions and Select Featured Speakers for Science and Research Tracks for 2023 Conference
Dr. Roland Griffiths Announced to Lead Discussions on the Science and Research of Psychedelics Featured Speakers Includes Dr. Matthew Johnson,...
ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF
Fremont, CA, April 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call
MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on...
BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Doheny Eye Institute Announces Upcoming Presentations at ARVO 2023 Annual Meeting
More than 30 Doheny Scientists and Clinician-Scientists Selected to Give Talks and Present Papers and Posters; Also Hosting a Breakfast...
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023
Data accepted as AAN Late-Breaking AbstractTHE WOODLANDS Texas, April 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today...
Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...
Aurora Spine to Attend the American Association of Neurological Surgeons Annual Meeting
Carlsbad, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a...
Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy
BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMSMALVERN, Pa., April 13, 2023 (GLOBE NEWSWIRE) -- Neuronetics,...
Cerevance Announces Poster Presentation at the BNA International Festival of Neuroscience
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous...
ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310
TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 10, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology...
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai
Exhibition will run from March 31st to May 21st, 2023, at Prada Rong ZhaiScientific Conference will be held on April...
RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders
Glen Rock, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a...
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
- Investor call to be held at 9:00 a.m. ET on April 18, 2023 -CAMBRIDGE, Mass., April 05, 2023 (GLOBE...
AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
Significant reduction of toxic protein aggregate, Poly(GP) Significant increase in biomarker of target engagement, sGPNMB AIT-101 and active metabolites crossed...
